» Articles » PMID: 21347327

Modeling Retinal Degeneration Using Patient-specific Induced Pluripotent Stem Cells

Overview
Journal PLoS One
Date 2011 Feb 25
PMID 21347327
Citations 113
Authors
Affiliations
Soon will be listed here.
Abstract

Retinitis pigmentosa (RP) is the most common inherited human eye disease resulting in night blindness and visual defects. It is well known that the disease is caused by rod photoreceptor degeneration; however, it remains incurable, due to the unavailability of disease-specific human photoreceptor cells for use in mechanistic studies and drug screening. We obtained fibroblast cells from five RP patients with distinct mutations in the RP1, RP9, PRPH2 or RHO gene, and generated patient-specific induced pluripotent stem (iPS) cells by ectopic expression of four key reprogramming factors. We differentiated the iPS cells into rod photoreceptor cells, which had been lost in the patients, and found that they exhibited suitable immunocytochemical features and electrophysiological properties. Interestingly, the number of the patient-derived rod cells with distinct mutations decreased in vitro; cells derived from patients with a specific mutation expressed markers for oxidation or endoplasmic reticulum stress, and exhibited different responses to vitamin E than had been observed in clinical trials. Overall, patient-derived rod cells recapitulated the disease phenotype and expressed markers of cellular stresses. Our results demonstrate that the use of patient-derived iPS cells will help to elucidate the pathogenic mechanisms caused by genetic mutations in RP.

Citing Articles

Cell Therapy for Retinal Degenerative Diseases: Progress and Prospects.

Wu K, Dhaliwal J, Sasitharan A, Kalevar A Pharmaceutics. 2024; 16(10).

PMID: 39458628 PMC: 11510658. DOI: 10.3390/pharmaceutics16101299.


Modeling inherited retinal diseases using human induced pluripotent stem cell derived photoreceptor cells and retinal pigment epithelial cells.

Seah I, Goh D, Banerjee A, Su X Front Med (Lausanne). 2024; 11:1328474.

PMID: 39011458 PMC: 11246861. DOI: 10.3389/fmed.2024.1328474.


Exploring Stem-Cell-Based Therapies for Retinal Regeneration.

Radu M, Branisteanu D, Pirvulescu R, Dumitrescu O, Ionescu M, Zemba M Life (Basel). 2024; 14(6).

PMID: 38929652 PMC: 11204673. DOI: 10.3390/life14060668.


Application of patient-derived induced pluripotent stem cells and organoids in inherited retinal diseases.

Liang Y, Sun X, Duan C, Tang S, Chen J Stem Cell Res Ther. 2023; 14(1):340.

PMID: 38012786 PMC: 10683306. DOI: 10.1186/s13287-023-03564-5.


On the utilization of the induced pluripotent stem cell (iPSC) model to study substance use disorders: A scoping review protocol.

Niemis W, Peterson S, Javier C, Nguyen A, Subiah S, Palmer R PLoS One. 2023; 18(10):e0292238.

PMID: 37824561 PMC: 10569547. DOI: 10.1371/journal.pone.0292238.


References
1.
Sung C, Davenport C, Nathans J . Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa. Clustering of functional classes along the polypeptide chain. J Biol Chem. 1993; 268(35):26645-9. View

2.
Raya A, Rodriguez-Piza I, Guenechea G, Vassena R, Navarro S, Barrero M . Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature. 2009; 460(7251):53-9. PMC: 2720823. DOI: 10.1038/nature08129. View

3.
Berson E, Rosner B, Sandberg M, Hayes K, Nicholson B, Willett W . A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993; 111(6):761-72. DOI: 10.1001/archopht.1993.01090060049022. View

4.
Ikeda H, Osakada F, Watanabe K, Mizuseki K, Haraguchi T, Miyoshi H . Generation of Rx+/Pax6+ neural retinal precursors from embryonic stem cells. Proc Natl Acad Sci U S A. 2005; 102(32):11331-6. PMC: 1183536. DOI: 10.1073/pnas.0500010102. View

5.
Hirami Y, Osakada F, Takahashi K, Okita K, Yamanaka S, Ikeda H . Generation of retinal cells from mouse and human induced pluripotent stem cells. Neurosci Lett. 2009; 458(3):126-31. DOI: 10.1016/j.neulet.2009.04.035. View